Cost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar
Implementing pharmacogenetic testing to guide antidepressant use was found to improve population health outcomes, while also significantly reducing health system costs.
Authors
- Wadha Al‐Muftah (ORCID: https://orcid.org/0000-0003-2549-082X)
- Daoud Al‐Badriyeh (ORCID: https://orcid.org/0000-0001-7791-954X)
- Oraib Abdallah (ORCID: https://orcid.org/0000-0003-4180-4235)
- Asma Althani (ORCID: https://orcid.org/0000-0002-6046-1541)
- Noriya Al‐Khuzaei
- Wafa Ziad Al-Marridi
- Dina Abushanab (ORCID: https://orcid.org/0000-0002-4162-8617)
- Rania Abdellatif (ORCID: https://orcid.org/0000-0002-3770-7128)
- Said I. Ismail (ORCID: https://orcid.org/0000-0002-8425-4010)
- Shaban Mohammed
- Moza Al Hail
Institutions
- Hamad Medical Corporation (QA)
- Qatar University (QA)
- Qatar Foundation (QA)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1080/20523211.2024.2410197
- Citations
- 3
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- Hamad Medical Corporation